ResearchMoz

Macular Degeneration Therapeutics Market in Asia-Pacific to 2019 - Existing Angiogenics Retain Dominance Though High Unmet Need Remains

GBI Research
Published Date » 2013-10-31
No. Of Pages » N/A
   
 GBI Research has released its research, “ Macular Degeneration Therapeutics Market in Asia-Pacific to 2019 - Existing Angiogenics Retain Dominance Though High Unmet Need Remains”, which provides in-depth insights into the macular degeneration market forecast until 2019 for the Asia-Pacific (APAC) region covering the four countries of Australia, China, India and Japan. It also covers disease epidemiology; treatment algorithms; treatment patterns; an in-depth analysis of clinical trials including failure rate analysis, pipeline analysis; and an analysis of deals relevant to macular degeneration. Apart from these the report also includes a heat map for the macular degeneration marketed products.  
   
 GBI Research analysis shows that the APAC ophthalmology market...
Table of Content

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Macular Degeneration Asia-Pacific Market to 2019 – Introduction
2.1 Symptoms
2.2 Etiology
2.3 Pathophysiology
2.3.1 Disease Initiation
2.3.2 Disease Propagation
2.4 Classification
2.4.1 Early AMD
2.4.2 Intermediate AMD
2.4.3 Advanced AMD
2.5 Co-morbidities and Complications
2.6 Diagnosis
2.6.1 History
2.6.2 Examination
2.6.3 Diagnostic Tests
2.7 Epidemiology
2.8 Prognosis and Disease Staging
2.9 Treatment Options
2.9.1 Pharmacological
2.9.2 Treatment Algorithms and Prescribing Habits
2.9.3 Non-pharmacological Care

3 Macular Degeneration Asia-Pacific Market to 2019 – Marketed Products
3.1 Therapeutic Landscape
3.1.1 Lucentis (ranibizumab) – Novartis AG/Roche (Genentech)
3.1.2 Eylea (aflibercept) – Regeneron Pharmaceuticals/Bayer Healthcare
3.1.3 Avastin (bevacizumab) – Genentech (Roche)
3.1.4 Macugen (pegaptanib sodium) – Valeant Pharmaceuticals/Pfizer
3.1.5 Visudyne (verteporfin injection) – Novartis AG
3.1.6 Triamcinolone Acetonide
3.2 Comparative Efficacy and Safety

4 Macular Degeneration Asia-Pacific Market to 2019 – Pipeline for Disease
4.1 Overall Pipeline
4.2 Pipeline Analysis by Molecule Type
4.3 Pipeline Analysis by Mechanism of Action
4.4 Clinical Trials
4.4.1 Failure Rate
4.4.2 Clinical Trial Duration
4.4.3 Clinical Trial Size
4.5 Promising Drug Candidates in the Pipeline
4.5.1 MC-1101 – MacuCLEAR, Inc.
4.5.2 KH902 (Fumintide) – Chengdu Kanghong Pharmaceuticals Group Co., Ltd.

5 Macular Degeneration Asia-Pacific Market to 2019 – Market Forecast to 2019
5.1 Geographical Markets
5.1.1 APAC Market
5.1.2 Australia
5.1.3 China
5.1.4 India
5.1.5 Japan
5.2 Drivers and Barriers for the Disease Market
5.2.1 Drivers
5.2.2 Barriers

6 Macular Degeneration Asia-Pacific Market to 2019 – Deals and Strategic Consolidations
6.1 Deals Analysis
6.2 Major Co-development Deals
6.2.1 Sinphar Enters into Co-development Agreement with MacuCLEAR
6.2.2 Allergan Enters into Co-development Agreement with Molecular Partners
6.2.3 X-Body BioSciences Enters into Co-development Agreement with Hengrui Medicine for AMD
6.2.4 Alcon Enters into Collaboration with AstraZeneca
6.2.5 Acucela Enters into Co-Development Agreement with Otsuka Pharma for ACU-4429
6.3 Major Licensing Deals
6.3.1 Allegro Ophthalmics Enters into Licensing Agreement with Senju Pharma to Develop Integrin Peptide Therapy
6.3.2 Allergan Enters into Licensing Agreement with Molecular Partners
6.3.3 PanOptica Enters into Licensing Agreement with OSI Pharma
6.3.4 Lpath Enters into Licensing Agreement with Pfizer
6.3.5 Shionogi Enters into Licensing Agreement with OncoTherapy Science

7 Macular Degeneration Asia-Pacific Market to 2019 – Appendix
7.1 All Pipeline Drugs by Phase
7.1.1 Discovery
7.1.2 Preclinical
7.1.3 IND-filed and Phase 0
7.1.4 Phase I
7.1.5 Phase II
7.1.6 Phase III
7.1.7 Undisclosed
7.2 Market Forecasts to 2019
7.2.1 Asia-Pacific
7.2.2 Australia
7.2.3 China
7.2.4 India
7.2.5 Japan
7.3 Market Definitions
7.4 Abbreviations
7.5 References
7.6 Research Methodology
7.6.1 Coverage
7.6.2 Secondary Research
7.6.3 Primary Research
7.6.4 Therapeutic Landscape
7.6.5 Geographical Landscape
7.6.6 Pipeline Analysis
7.7 Expert Panel Validation
7.8 Contact Us
7.9 Disclaimer

List of Tables


Table 1: Macular Degeneration Market, Classification of AMD
Table 2: Macular Degeneration Market, Treatment Recommendations and Follow-up for Non-neovascular AMD
Table 3: Macular Degeneration Market, Treatment Recommendations and Follow-up for Neovascular AMD
Table 4: Macular Degeneration Market, Global, Pharmaceutical Pipeline (Discovery), 2013
Table 5: Macular Degeneration Market, Global, Pharmaceutical Pipeline (Preclinical), 2013
Table 6: Macular Degeneration Market, Global, Pharmaceutical Pipeline (IND/CTA-filed), 2013
Table 7: Macular Degeneration Market, Global, Pharmaceutical Pipeline (Phase I), 2013
Table 8: Macular Degeneration Market, Global, Pharmaceutical Pipeline (Phase II), 2013
Table 9: Macular Degeneration Market, Global, Pharmaceutical Pipeline (Phase III), 2013
Table 10: Macular Degeneration Market, Global, Pharmaceutical Pipeline (Undisclosed), 2013
Table 11: Macular Degeneration Market, Asia-Pacific, Market Forecast, 2012–2019
Table 12: Macular Degeneration Market, Australia, Market Forecast, 2012–2019
Table 13: Macular Degeneration Market, China, Market Forecast, 2012–2019
Table 14: Macular Degeneration Market, India, Market Forecast, 2012–2019
Table 15: Macular Degeneration Market, Japan, Market Forecast, 2012–2019

List of Figures


Figure 1: Macular Degeneration Market, Pathophysiology of AMD
Figure 2: Macular Degeneration Market, Types of Dry AMD
Figure 3: Macular Degeneration Market, Classification of AMD
Figure 4: Macular Degeneration Market, Amsler Grid Test
Figure 5: Macular Degeneration Market, Asia-Pacific, Epidemiology, 2012–2019
Figure 6: Macular Degeneration Market, Photodynamic Therapy
Figure 7: Macular Degeneration Market, Treatment Algorithm by Type and by Stage
Figure 8: Macular Degeneration Market, Fluorescein Angiogram Showing Laser Photocoagulation Images
Figure 9: Macular Degeneration Market, Global, Annual Sales ($m), 2012
Figure 10: Macular Degeneration Market, Lucentis, Global, Annual Sales ($m), 2006–2012
Figure 11: Macular Degeneration Market, Eylea, Global, Annual Sales ($m), 2011–2012
Figure 12: Macular Degeneration Market, Visudyne, Global, Annual Sales ($m), 2005–2012
Figure 13: Macular Degeneration, Global, Heat Map of Safety and Efficacy for Marketed Products
Figure 14: Macular Degeneration Market, Global, Pipeline, 2013
Figure 15: Macular Degeneration Market, Global, Pipeline, 2013
Figure 16: Macular Degeneration Market, Global, Pipeline, 2013
Figure 17: Macular Degeneration Market, Global, Clinical Trial Failure Rate, 2013
Figure 18: Macular Degeneration Market, Global, Pipeline, Clinical Trial Duration, 2013
Figure 19: Macular Degeneration Market, Global, Pipeline, Clinical Trial Size, 2013
Figure 20: Macular Degeneration Market, Global, Annual Sales ($bn), 2012–2019
Figure 21: Macular Degeneration Market, Australia, Annual Sales ($m), 2012–2019
Figure 22: Macular Degeneration Market, China, Annual Sales ($m), 2012–2019
Figure 23: Macular Degeneration Market, India, Annual Sales ($m), 2012–2019
Figure 24: Macular Degeneration Market, Japan, Annual Sales ($m), 2012–2019
Figure 25: Macular Degeneration Market, Global, Deals, 2007–2013
Figure 26: Macular Degeneration Market, Global, Co-development Deals, 2007–2013
Figure 27: Macular Degeneration Market, Global, Licensing Deals, 2007–2013
Figure 28: GBI Research Market Forecasting Model

Upcoming Reports:

Poland: market of prepared feeds for farm animals
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the prepared feeds for farm animals market in Poland and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the prepared feeds for farm animals market in Poland, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report...
Animal Antimicrobials and Antibiotics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020
By - Transparency Market Research
Animal antimicrobials and antibiotics are typically used in the husbandry of livestock animals; which comprises not only prophylaxis or treatment of infection but also the use of sub therapeutic doses of these drugs in animal feed to improve feed efficiency. Antimicrobials and antibiotics are used by livestock owners as wells as by veterinarians to improve health of livestock; and also to increase the size of poultry, livestock as well as of other farmed animals. However, the uses of animal antibiotics are banned in some countries such as U.S. owing to food contamination and rising...
Packaged Food Market - Global Industry Size, Market Share, Trends, Analysis, And Forecasts 2012 - 2018
By - Transparency Market Research
Some of the factors driving packaged food market are increasing popularity of quick service restaurants, modern retail trade, technological improvements, and changing lifestyle.  The market is gaining momentum due to rise in demand for packaged food in developed economies. Another important factor responsible for growth of the packaged food industry is the rise in the commodity prices that results in increased cooking at home, in response to economic slowdown.  Market Segmentation  Based on different product segments : Confectionery...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Private Schools Have Higher Male Teaching Staff Than State Schools: Report
Oct 22, 2014  
Private and state education has always been a matter of debate across the UK. A recent study has shown that when it comes to teaching employment options, the difference between state-run and private education in terms of gender balance is absolutely clear.  A report by the Independent Schools Council (ISC) shows that while women dominate both the education medium, the number of...
Abbots First Australian Renewable Energy Deal Rejected
Oct 22, 2014  
The Abbot government’s initial deal for a renewable energy plan has been immediately rejected by the clean energy industry and Labor. The negotiations are about a bipartisan agreement regarding the future of the Australian renewable energy target. The Labor party rejected the first plan as being a job-killer before it was even announced. The plan, they said, would protect solar...
Chemical Production in Europe Flatlines in First Seven Months of 2014
Oct 21, 2014  
The recently published report by European Chemical Industry Council (Cefic) shows overall chemical production in Europe has flatlined in first seven months of this year. Though the initial four months showed a positive trend, the production volumes dropped in July 2014 and in the following months as well. The contraction in output in the three consecutive months has nullified the upward trend...
Actavis to Compete for Omega Pharma
Oct 20, 2014  
Actavic Plc has declared that it will become one of the bidders for the Omega Pharma NV deal, as the United States based drug maker keeps searching for more takeovers. Actavis will be competing against Boehringer Ingelheim GmbH, Sanofi and Perrigi Co. for Omega Pharma. Actavis places themselves as a potential suitor along with quarry in a multitude of potential pharma combinations....
Sale of iPhone Fuels UKs s
Oct 20, 2014  
With the sale of Apple Inc.’s latest smartphone, consumer expenditure on electronics has registered a three-year high this September. The new iPhone 6 and iPhone 6 Plus were launched in the U.K. on September 19 and buyers from across the country raced to purchase the newest smartphone. Both these smartphones are so far the fastest selling Apple products with a sale of over 10 million...